Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of AD-223
Condition or disease : hypertension
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test group | Experimental | AD-223A+AD-223B+AD-223C Placebo |
|
| Control group 1 | Active Comparator | AD-223A+AD-223B Placebo+AD-223C Placebo |
|
| Control group 2 | Active Comparator | AD-223A Placebo+AD-223B+AD-223C Placebo |
|
| Control group 3 | Active Comparator | AD-223A Placebo+AD-223B Placebo+AD-223C |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-223A | Drug | PO, Once daily(QD), 8weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change rate of MSSBP | Change from baseline in mean sitting systolic blood pressure | Baseline, Week 8 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jin Ho Shin, M.D., Ph.D | Hanyang University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hanyang University Hospital | Seoul | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42130156 | Derived | Ahn HS, Ahn JC, Cho JM, Lim KH, Han SH, Cho YK, Kim KH, Hong SJ, Lee CJ, Na JO, Sung KC, Choi K, Kim SY, Kim DH, Lee HC, Ihm SH, Youn JC, Choi JY, Kim SH, Kim KI, Sung JH, Pyun WB, Kim WS, Cho JS, Lee Y, Her SH, Cho EJ, Lee EM, Lee HY, Yoon YW, Lee JH, Kim W, Rhee SJ, Shin J. Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial. J Clin Hypertens (Greenwich). 2026 May;28(5):e70279. doi: 10.1111/jch.70279. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AD-223B |
| Drug |
PO, Once daily(QD), 8weeks |
|
| AD-223C | Drug | PO, Once daily(QD), 8weeks |
|
| AD-223A Placebo | Drug | PO, Once daily(QD), 8weeks |
|
| AD-223B Placebo | Drug | PO, Once daily(QD), 8weeks |
|
| AD-223C Placebo | Drug | PO, Once daily(QD), 8weeks |
|